In this review:
Ofatumumab vs teriflunomide in RMS: the ASCLEPIOS I and II trials
Inebilizumab for NMOSD: the N-MOmentum study
Preliminary safety and efficacy of ATA188 for progressive MS
Ponesimod vs teriflunomide in relapsing MS: the OPTIMUM study
Natalizumab treatment during pregnancy
Risk factors for a clinical event in radiologically isolated syndrome
Disability progression unrelated to relapses in RRMS
Alemtuzumab maintains its efficacy over 9 years in RRMS
Human herpesvirus and MS aetiology
Excess mortality in patients with RRMS
Please login below to download this issue (PDF)